Literature DB >> 24519864

Interaction between phosphorus and parathyroid hormone in non-dialysis CKD patients under nephrology care.

Luca De Nicola1, Giuseppe Conte, Paolo Chiodini, Pierluigi D'Angiò, Gerardo Donnarumma, Roberto Minutolo.   

Abstract

BACKGROUND: Whether the traditional treatment of chronic kidney disease (CKD)-mineral and bone disorder is effective in the setting of tertiary nephrology care is an unexplored question. We evaluated phosphate, calcium and PTH levels during the first year of nephrology care and the prognostic role of month-12 levels in non-dialysis patients referred prior to availability of the novel P binders.
METHODS: We studied a historical cohort of consecutive patients with CKD stage 3-5 at referral (baseline), and after 6 and 12 months of nephrology care; thereafter, patients were followed for renal survival (time to death or end-stage renal disease).
RESULTS: At month 12, versus baseline, we detected a larger implementation of dietary protein restriction (P = 0.001), vitamin D and P binder (P < 0.0001 for both). Mean serum P remained unchanged (4.02 ± 0.77, 4.01 ± 0.79, 4.10 ± 0.85 mg/dL at baseline, month 6 and 12, respectively) with only 18, 16 and 21 % patients showing uncontrolled serum P at the three study visits. Similarly, calcium levels were unchanged and within the target in most cases. Conversely, intact PTH increased from 102 pg/mL (interquartile range 67-139) to 113 (68-179), P = 0.015, with 59, 60 and 53 % patients showing high values at the three study visits. During the subsequent follow-up (31 months), 96 renal deaths occurred. Cox analysis evidenced a significant prognostic role of the interaction P × PTH (P = 0.002), that is, the risk of renal death associated with serum P increased in the presence of higher PTH.
CONCLUSIONS: In patients under nephrology care, P and PTH should be considered in concert to optimize risk stratification for renal death.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24519864     DOI: 10.1007/s40620-013-0001-8

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  37 in total

1.  K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2003-10       Impact factor: 8.860

Review 2.  Oral phosphate binders in patients with kidney failure.

Authors:  Marcello Tonelli; Neesh Pannu; Braden Manns
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

3.  Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges.

Authors:  Lourdes Craver; Maria Paz Marco; Isabel Martínez; Montserrat Rue; Merce Borràs; Maria Luisa Martín; Felipe Sarró; José Manuel Valdivielso; Elvira Fernández
Journal:  Nephrol Dial Transplant       Date:  2007-01-05       Impact factor: 5.992

4.  Association of disorders in mineral metabolism with progression of chronic kidney disease.

Authors:  Stephan Schwarz; Bhairvi K Trivedi; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  Clin J Am Soc Nephrol       Date:  2006-05-17       Impact factor: 8.237

5.  Timing of onset of CKD-related metabolic complications.

Authors:  Olivier Moranne; Marc Froissart; Jerome Rossert; Cedric Gauci; Jean-Jacques Boffa; Jean Philippe Haymann; Mona Ben M'rad; Christian Jacquot; Pascal Houillier; Benedicte Stengel; Bruno Fouqueray
Journal:  J Am Soc Nephrol       Date:  2008-11-12       Impact factor: 10.121

6.  Prognosis of CKD patients receiving outpatient nephrology care in Italy.

Authors:  Luca De Nicola; Paolo Chiodini; Carmine Zoccali; Silvio Borrelli; Bruno Cianciaruso; Biagio Di Iorio; Domenico Santoro; Vincenzo Giancaspro; Cataldo Abaterusso; Ciro Gallo; Giuseppe Conte; Roberto Minutolo
Journal:  Clin J Am Soc Nephrol       Date:  2011-08-04       Impact factor: 8.237

7.  Mineral metabolites and CKD progression in African Americans.

Authors:  Julia J Scialla; Brad C Astor; Tamara Isakova; Huiliang Xie; Lawrence J Appel; Myles Wolf
Journal:  J Am Soc Nephrol       Date:  2012-12-14       Impact factor: 10.121

8.  Cardiovascular effects of sevelamer in stage 3 CKD.

Authors:  Colin D Chue; Jonathan N Townend; William E Moody; Daniel Zehnder; Nadezhda A Wall; Lorraine Harper; Nicola C Edwards; Richard P Steeds; Charles J Ferro
Journal:  J Am Soc Nephrol       Date:  2013-04-18       Impact factor: 10.121

9.  Influence of extracellular fluid volume expansion on magnesium, calcium and phosphate handling along the rat nephron.

Authors:  P Poujeol; D Chabardes; N Roinel; C De Rouffignac
Journal:  Pflugers Arch       Date:  1976-09-30       Impact factor: 3.657

10.  On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog.

Authors:  E Slatopolsky; S Caglar; J P Pennell; D D Taggart; J M Canterbury; E Reiss; N S Bricker
Journal:  J Clin Invest       Date:  1971-03       Impact factor: 14.808

View more
  1 in total

1.  Prognosis and determinants of serum PTH changes over time in 1-5 CKD stage patients followed in tertiary care.

Authors:  Silvio Borrelli; Paolo Chiodini; Luca De Nicola; Roberto Minutolo; Michele Provenzano; Carlo Garofalo; Giuseppe Remuzzi; Claudio Ronco; Mario Gennaro Cozzolino; Carlo Manno; Anna Maria Costanzo; Giuliana Gualberti; Giuseppe Conte
Journal:  PLoS One       Date:  2018-08-23       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.